Business Wire

BOEHRINGER-INGELHEIM

14.9.2023 10:11:25 CEST | Business Wire | Press release

Share
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets from the Science Based Targets initiative (SBTi). This validation underlines the company’s commitment to aligning its efforts to tackle climate change and reduce global warming in line with the 2015 Paris Agreement. The SBTi drives ambitious climate action in the private sector, by enabling organizations to set science-based emissions reduction targets, while maximizing transparency, accountability, and corporate leadership through annual disclosure and progress against the targets.

“Driving environmental stewardship to decarbonize our business operations, both within and beyond the factory gates, has been a long-time priority at Boehringer Ingelheim,” said Felix Gutsche, Boehringer Ingelheim’s Head of Corporate Strategy & Consulting. “Having our emissions reduction targets approved by a respected organization like SBTi confirms that our efforts align with the current global agenda.”

In 2021 Boehringer Ingelheim committed reducing absolute scope 1 and 2 GHG emissions1 by 58.9 percent and absolute scope 3 GHG emissions2 by 27.5 percent (from a 2019 base year). The recent SBTi verification underscores Boehringer Ingelheim’s ongoing efforts.

The company recently added its production sites Fornovo (Italy) and Paulínia (Brazil) to its list of carbon-neutral certified sites, bringing the total to seven worldwide. This achievement resulted amongst others from the purchase and installation of renewable energy solutions, as well as ambitious carbon reduction measures. At other sites, including Dortmund and Katharinenhof (Germany), Gainesville (USA), Sant Cugat (Spain), and Zhangjian (China) the company initiated the integration of circular economy principles into development and manufacturing processes, green mobility concepts, as well as sustainability building standards, e.g., Leadership in Energy and Environmental Design (LEED) certification for office buildings.

Boehringer Ingelheim’s efforts to implement its low-carbon transformation are driven through the MORE GREEN pillar within its Sustainable Development - For Generations program. To foster low-carbon technologies and solutions, Boehringer Ingelheim applies an internal carbon price of EUR 100 per ton CO2 emissions for investments, which has been fully established at all sites. The company also emphasizes environmental sustainability in larger projects, providing another EUR 130 million for projects that contribute to the global MORE GREEN goals. This fund has now initiated over 60 new environmental sustainability projects since 2020.

To support certified climate contribution projects that help mitigate the environmental impact of currently unavoidable emissions, Boehringer Ingelheim continues to partner with ClimateSeed. This reputable social enterprise offers a broad portfolio of internationally recognized Verified Emissions Reduction projects that not only safeguard biodiversity and ecosystem services, but also benefit local communities.

Click here for the full release: https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-green/boehringer-receives-sbti-validation-co2-reduction

References:
1Scope 1 emissions are direct emissions from owned or controlled sources. Scope 2 emissions are indirect emissions from the generation of purchased energy.
2Scope 3 GHG emissions are emissions from purchased goods and services, capital goods, fuel and energy related activities, upstream transportation and distribution and use of sold products.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230914610507/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye